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Summary
Background.— Compared with administration in the catheterization laboratory, early treatmentinfarction;
Tiroﬁban;
Glycoprotein IIb/IIIa
with glycoprotein IIb/IIIa inhibitors provides beneﬁts to patients with ST-segment elevation
myocardial infarction who undergo primary percutaneous intervention. Whether this beneﬁt is
maintained on top of a 600mg loading dose of clopidogrel is unknown.
∗ Corresponding author. Soins Intensifs et Urgences Cardiologiques, pôle Coeur-Poumon Métabolisme, CHU de Lyon, 28, Doyen-Lépine,
69677 Bron, France.
E-mail addresses: eric.bonnefoy-cudraz@chu-lyon.fr, eric.bonnefoy-cudraz@adm.univ-lyon1.fr (E. Bonnefoy).
1 A complete list of AGIR-2 investigators and personnel can be
found in the appendix.
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inhibitor;
Prehospital care;
Primary angioplasty
initial TIMI 2 or 3 ﬂow of the infarct-related artery or complete ST-segment resolution after
coronary intervention compared with initiation of tiroﬁban in the catheterization laboratory
MOTS CLÉS
Infarctus du
myocarde ;
Tiroﬁban ;
Inhibiteur du
glycoprotéine
IIb/IIIa ;
Soins préhospitalier ;
Angioplastie primaire
préhospitalière du tiroﬁban en plus d’une dose de charge de 600mg de clopidogrel n’améliore
ni les valeurs initiales de ﬂux TIMI 2 ou 3 dans l’artère responsable de l’infarctus, ni l’évolution
t ST en postprocédure d’angioplastie.
. Tous droits réservés.
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bbreviations
TEMI ST-segment elevation myocardial infarction
MI acute myocardial infarction
CI percutaneous coronary intervention
P IIb/IIIa glycoprotein IIb/IIIa
IMI thrombolysis in myocardial infarction
RA infarct-related artery
n-TIME2 Ongoing tiroﬁban in myocardial infarction evalu-
ation2
RAVE 3 Bavarian reperfusion alternatives evaluation-3
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n patients undergoing primary percutaneous intervention
PCI), glycoprotein (GP) IIb/IIIa inhibitors improve angio-
raphic and clinical outcome [1] and are a class IIa
ecommendation [2]. Compared with administration in the
atheterization laboratory (cath lab), early initiation of GP
Ib/IIIa inhibitors in the emergency department or the ambu-
ance had been associated with a better recanalization rateC. El Khoury et al.
Methods.— In a multicentre, controlled, randomized study, 320 patients with ST-segment ele-
vation myocardial infarction undergoing primary percutaneous coronary intervention received
a high-dose bolus of tiroﬁban given either in the ambulance (prehospital group) or in
the catheterization laboratory. The primary endpoint was a TIMI ﬂow grade 2—3 of the
infarct-related vessel at initial angiography. Secondary endpoints included ST-segment res-
olution 1 h after percutaneous coronary intervention and peak serum troponin I concent-
ration.
Results.— Tiroﬁban was administered 48 (95% conﬁdence interval 21.4—75.0) min earlier in
the prehospital group. At initial angiography, the combined incidence of TIMI 2—3 ﬂow was
39.7% in the catheterization-laboratory group and 44.2% in the prehospital group (p = 0.45). No
difference was found on postpercutaneous intervention angiography or peak troponin concen-
tration. Complete ST-segment resolution 60min after the start of intervention was 55.4% in the
catheterization-laboratory group and 52.6% in the prehospital group (p = 0.32).
Conclusion.— Prehospital initiation of high-dose bolus tiroﬁban did not improve signiﬁcantly(NCT00538317).
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Contexte.— L’administration d’un anti-GPIIb/IIIa très en amont de l’admission en salle de
cathétérisme augmente le taux de reperfusion des patients qui bénéﬁcient d’une angioplas-
tie primaire. La persistance du bénéﬁce de cette administration précoce chez des patients qui
rec¸oivent en préhospitalier une dose de 600mg de clopidogrel n’est pas connue.
Méthodes.— Dans cette étude multicentrique, contrôlée et randomisée, 320 patients présen-
tant un STEMI et bénéﬁciant d’une angioplastie primaire ont rec¸u une dose de charge de 600mg
de clopidogrel et du tiroﬁban soit dans l’ambulance (groupe pré-Hosp) soit directement en salle
de cathétérisme (groupe cath Lab). Le critère de jugement principal était un ﬂux TIMI 2—3 dans
l’artère coronaire coupable lors de la première injection. Les critères de jugement secondaires
incluaient la résolution du sus-décalage du segment ST une heure après l’angioplastie primaire
et le pic de troponine I.
Résultats.— Le tiroﬁban a été administré 48minutes (IC95 % : 21,4—75,0) plus tôt dans le groupe
pré-Hosp. À l’angiographie initiale, la proportion des ﬂux TIMI 2—3 était de 39,7 % dans le groupe
cath Lab et de 44,2% dans le groupe pré-Hosp (P = 0,45). Aucune différence signiﬁcative n’a
été observée entre les deux groupes pour les résultats angiographiques postprocédure ou le
pic de troponine I. La résolution complète du sus-décalage du segment ST, 60minutes après
l’angioplastie était de 55,4 % dans le groupe cath Lab contre 52,6 % dans le groupe pré-Hosp
(p = 0,32).
Conclusion.— Comparée à une administration en salle de cathétérisme, l’administration3].
Most studies comparing early and late administration
f GP IIb/IIIa inhibitors were performed before the gen-
ralization of adjuvant antiplatelet aggregation with high
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SPrehospital vs cath-lab tiroﬁban in primary PCI
loading-dose clopidogrel. Loading with 600mg of clopidogrel
provides a high degree of platelet-aggregation inhibition
within a short time [4]. With a 600mg clopidogrel regimen,
prehospital administration of high-dose tiroﬁban was asso-
ciated with an improved ST-segment resolution compared
with placebo [5].
However, prehospital tiroﬁban has not been compared
with tiroﬁban given in the cath lab in the modern era of adju-
vant antiplatelet therapy in patients undergoing primary
PCI. It is not only a clinical question but also an organiza-
tional problem. If applied widely, the systematic prehospital
administration of GP IIb/IIIa inhibitors would raise the cost
and complexity of prehospital protocols for the management
of ST-segment elevation myocardial infarction (STEMI). We
therefore performed a multicentre, prospective randomized
trial to evaluate the extent of the beneﬁt of prehospital
tiroﬁban compared with cath-lab tiroﬁban on top of a high
loading-dose of clopidogrel in patients undergoing primary
PCI.
Methods
Study patients
The study recruited out-of-hospital patients managed by
mobile intensive care units (MICU) staffed by a physician.
The study was conducted within the organization of the
RESCUe and RESURCOR networks that associate 12 tertiary
cardiology centres with a round-the-clock catheterization
laboratory, six medical dispatching centres and 20 MICU ser-
vices. Patients were eligible for inclusion if they presented
within 12 h after the onset of symptoms of myocardial infarc-
tion, i.e., characteristic pain lasting for at least 30min
and not responsive to nitrates, and electrocardiographic
ST-segment elevation ≥ 0.2mV in two or more contigu-
ous precordial leads or 0.1mV for limb leads. Patients
were excluded if they were known to have haemorrhagic
diathesis; were pregnant; had any allergy or contraindica-
tion to heparin, aspirin or tiroﬁban; suffered from severe
renal or hepatic insufﬁciency; had had major surgery within
the past month; had any sign of cerebral ischaemic dis-
ease for < 1 month or non-ischaemic disease whatever its
date; had received oral anticoagulant treatment, a ﬁbri-
nolytic or a GP IIb/IIIa antagonist within the past 7 days;
had uncontrolled hypertension, severe conduction disor-
der or cardiogenic shock; or if duration of transfer to
the hospital (entrance to the cath lab) was to exceed
1 h.
The study protocol was approved by the hospital and
regional ethics committees. Oral informed consent was
required in the ambulance and written consent was obtained
from all patients no later than the time of catheterization.
Randomisation and treatment strategies
After initial screening and patient consent, open-label ran-
domisation was conferred at the site of initial management
(usually at home or at the patient’s workplace) to high-
dose tiroﬁban in the ambulance (prehospital group) or in
the catheterization laboratory (cath-lab group). Randomi-
sation was done in dispatching medical centres according to
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computer-generated random sequence enclosed in scratch
ards.
All patients received, in the prehospital setting, a load-
ng dose of 600mg of clopidogrel, a 60 IU/kg intravenous
IV) heparin bolus (maximum dose 5000 IU) and 250—500mg
spirin (oral or IV). Patients were transported immediately
o the hospital for coronary angiography and angioplasty
henever possible.
Open-label tiroﬁban was administered as soon as possi-
le at the site of initial management in patients assigned
o the prehospital group, and at the admission to the cath
ab before vascular access in those assigned to the cath-lab
roup. A loading dose of 25g/kg was administered in 3min
ollowed by an infusion of 0.15g/kg per min for 18—24 h.
Angioplasty was performed according to local standards
ith the intention of re-establishing blood ﬂow in the
nfarct-related artery as soon as possible.
Electrocardiograms, biological data and procedural
eports were collected and analysed centrally. Data on
oronary angiograms were reported by the investigators. If
iscrepancies appeared between the case-report form and
he procedural report, a request was sent to the investiga-
or for further details. Electrocardiograms were recorded at
resentation, on admission to the cath-lab and 1 h after PCI
r angiography if no PCI was performed. They were collected
nd analysed centrally according to the same protocol by
wo trained research monitors unaware of the therapeutic
trategy. ST-segment elevation was measured in all leads to
he nearest 0.5mm at 60ms after the J point with hand-held
allipers. ST-segment resolution was deﬁned as the ratio
etween cath-lab or 60min post-PCI values and the initial
um of ST-segment elevation.
Creatine kinase and troponin I concentrations were mea-
ured on admission, after the procedure, and every 6 h for
4 h, then every day until discharge.
ndpoints
he primary endpoint was the presence of TIMI 2 or 3
ow in the culprit artery during the ﬁrst injection in coro-
ary angiography. Secondary endpoints were sum residual
T-segment deviation and the frequency of ST-segment res-
lution 60min after the angioplasty, creatine kinase and
roponin peak serum concentrations. ST-segment resolu-
ion was considered complete when > 70% from baseline.
o allow comparison with previous studies [5], residual
T-segment deviation was stratiﬁed as 0mm, 1—3mm,
—6mm and > 6mm. Peak creatine kinase and peak troponin
ere deﬁned as the highest creatine kinase and troponin
serum concentrations within the ﬁrst 48 h. Clinical and
afety endpoints were in-hospital death, reinfarction, acute
tent thrombosis or major bleeding. Major bleeding was
eﬁned as signs of haemorrhage associated with a drop
n haemoglobin > 50 g/L, excluding patients who underwent
oronary artery bypass graft surgery.
tatistical analysisontinuous data are presented as mean with standard devia-
ion or median with 25th and 75th quartiles unless otherwise
tated. Comparisons were made with Student’s t-test or
he Mann-Whitney U test. Discrete data are summarized as
288 C. El Khoury et al.
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higure 1. Flow of patients through the trial. AMI: acute myocard
requencies and comparisons were made with Pearson’s c2
est or Fisher’s exact test. The c2 test was also used to
est for trends in various grades of TIMI ﬂow, ST-segment
esolution and residual ST-segment elevation. A subgroup
nalysis was performed in patients managed early (before
he median time from symptom onset to arrival in the MICU)
r later (after the median time). Statistical analysis was per-
ormed on the basis of intention-to-treat. A p-value of < 0.05
as considered statistically signiﬁcant.
Based on the results of a previous meta-analysis [6], the
nitial sample size calculation was 300 patients with a 5%
lpha risk and an 80% power to detect a 16% difference
n the primary endpoint. The study population was set to
20 patients. Since some patients were wrongly randomised
ue to errors in the dispatching centre or withdrew their
nformed consent before angiography, the recruitment was
ncreased to 337 patients to reach at least 155 patients in
ach group. Incorrectly randomised patients were excluded
rom all analyses. The SAS software (Windows V 9.1) was
sed for all analyses.
The study is registered, number NCT00538317.
esults
linical data
rom July 2007 to July 2008, 320 patients with an out-of-
ospital diagnosis of STEMI and planned primary PCI were
ncluded and assigned randomly to prehospital tiroﬁban
n = 164) or cath-lab tiroﬁban (n = 156) (Fig. 1).
The baseline characteristics of the study population
ccording to treatment strategy are presented in Table 1.
c
(
p
o
dfarction. Cath lab: catheterization laboratory.
o statistically signiﬁcant difference was found in baseline
istribution of demographic, clinical and procedural charac-
eristics except for previous PCI, which was more frequent
n the cath-lab group.
Delays in patient management are shown in Table 1.
iroﬁban administration increased the transport time in the
rehospital group and the preangiographic time in the cath-
ab group. Tiroﬁban was administered 48 (95% conﬁdence
nterval 21.4—75.0) min earlier in the prehospital initiation
roup.
ngiographic and interventional results
ne patient in the prehospital group did not undergo angiog-
aphy because of changes in symptoms during transport
elated the evolving STEMI to an acute aortic dissection. The
ate of the primary endpoint —TIMI grade 2—3 ﬂow in the
ulprit artery— was 39.7% (62 patients) in the cath-lab group
nd 44.2% (72 patients) in the prehospital group (p = 0.42).
After initial angiography, 118 patients underwent throm-
us aspiration (51 patients [32.9%] in the cath-lab group;
7 patients [41.1%] in the prehospital group). Stents were
laced in 225 patients (113 [72.4%] and 112 [69.1%], respec-
ively). No PCI was performed in 50 (15.6%) patients, 24 of
hom had normal angiograms, 10 had unsuitable lesions,
even underwent coronary artery bypass graft surgery, ﬁve
ad delayed angioplasty and four for unknown reasons.
Slow-ﬂow occurred in 9.0% (n = 14) of patients in the
ath-lab group and in 9.1% (n = 15) in the prehospital group
p = 0.95). No differences in various grades of TIMI ﬂow
ost-PCI between the cath-lab and prehospital groups were
bserved on ﬁrst angiography and at the end of the proce-
ure (Fig. 2).
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Table 1 Baseline clinical characteristics.
Cath-lab initiation
of tiroﬁban (n = 156)
Prehospital initiation of
tiroﬁban (n = 164)
p
Men 124 (79.5) 123 (75.0) 0.34
Diabetes 17 (10.9) 18 (11.0) 0.98
Hypertension 62 (39.7) 74 (45.1) 0.33
Current smoker 56 (35.9) 61 (37.2) 0.81
Dyslipidaemia 67 (43.0) 55 (33.5) 0.08
Anterior myocardial infarction 68 (43.6) 84 (51.2) 0.17
Previous myocardial infarction 24 (15.4) 15 (9.1) 0.09
Previous coronary artery bypass
graft
6 (3.8) 2 (1.2) 0.13
Previous percutaneous coronary
intervention
23 (14.7) 13 (7.9) 0.05
Killip class≥ 2 13 (8.3) 19 (11.6) 0.33
Heart rate (beats/min) 75.4± 16.2 77.2± 22.2 0.42
Systolic arterial pressure (mmHg) 139± 28 141± 25 0.80
Cumulative ST-deviation on
diagnostic electrocardiogram
(mm)
12± 9 13± 8 0.25
Treatment delay, median [25—75%]
(min)
Onset of chest pain to MICU 98 [50—200] 104 [56—233] 0.30
MICU to cath lab 54 [45—69] 61 [54—74] 0.0002
Cath lab to ﬁrst angiography 26 [15—35] 21 [13—30] 0.007
MICU to ﬁrst angiography 83 [70—96] 85 [72—100] 0.46
Data presented as mean± SD or number (%) of patients unless otherwise stated. MICU: mobile intensive care unit arrival on site of
intervention; Cath lab: admission in the catheterization laboratory.
ST-segment analysis
Owing to insufﬁcient quality or for reasons relating to tim-
ing, an electrocardiogram was evaluated on admission to
Figure 2. Prepercutaneous coronary intervention (PCI) and
post-PCI epicardial ﬂow with catheterization laboratory versus pre-
hospital tiroﬁban administration. TIMI grade 3, 2 and 0—1 ﬂow at
ﬁrst angiography and at the end of intervention. TIMI: thrombolysis
in myocardial infarction.
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ghe cath-lab in 74.6% of patients (n = 239; 127 patients in
he cath-lab group and 112 in the prehospital group) and
0min after the procedure in 93.7% (n = 300; 148 patients
nd 152 patients, respectively).
On admission to the cath lab, there was a non-statistically
igniﬁcant trend toward a higher rate of complete ST-
egment resolution in the prehospital group (8.7% [11/127]
s 15.2% [17/112]; p = 0.11). After the procedure, no such
rend was apparent. Complete ST-segment resolution was
bserved in 55.4% (82/148) of patients in the cath-lab group
nd in 52.6% (80/152) in the prehospital group (p = 0.32).
arious grades of ST-segment resolution were similar in both
roups (Table 2).
An additional subgroup analysis compared the two treat-
ent strategies in patients who were managed very early,
ithin 100min of symptom onset, and those managed later
Fig. 3). In the early patients, there was a trend toward
lower rate of TIMI grade 2—3 ﬂow in the cath-lab group
39.7% [31/78] vs 51.2% [41/80]; p = 0.15). No such trend was
pparent for the complete ST-segment resolution endpoints.
or patients managed later, no differences were observed
or either endpoint in both groups.aboratory results
eak and 24 h serum concentrations of creatine kinase and
roponin I did not show a favourable trend in the prehospital
roup (Table 2).
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Table 2 Electrocardiogram and biological parameters.
Cath-lab initiation of tiroﬁban Prehospital initiation of tiroﬁban p
ST-segment resolution
In the cath lab n = 127 n = 112
> 70% 11 (8.7) 17 (15.2) 0.11
60min after angiography/PCI n = 148 n = 152
> 70% 82 (55.4) 80 (52.6) 0.32
> 50% 113 (76.3) 104 (68.4) 0.12
Residual ST-segment elevation
60min after angiography/PCI
n = 148 n = 152
4—6mm 33 (22.3) 31 (20.4)
> 6mm 20 (13.5) 38 (25.0) 0.07
Biological variables n = 152 n = 164
Peak creatine kinase (IU/L) 1860± 1568 2220± 2202 0.10
Creatine kinase (at 24 h) (IU/L) 1047± 907 1057± 928 0.90
Peak troponin I (ng/mL) 41.8± 68.7 57.9± 132.0 0.18
Troponin I (at 24 h) (ng/mL) 23.6± 34.3 30.6± 87.3 0.36
Data presented as mean± SD or number (%) of patients. PCI: percut
infarction.
Figure 3. Prepercutaneous coronary intervention (PCI) epicar-
dial ﬂow and 60min post-PCI complete ST-segment resolution with
catheterization laboratory (cath lab) versus prehospital tiroﬁban
administration. TIMI grade 2—3 ﬂow at ﬁrst angiography and com-
plete ST-segment resolution 1 h after PCI in patients who were
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microvascular and tissue-level reperfusion. In AGIR2, 1 hanagedwithin 100min of symptom onset (left part) and later (right
art) according to cath-lab (yellow) or prehospital (orange) tiroﬁban
dministration. TIMI: thrombolysis in myocardial infarction.
afety and in-hospital outcomes
ew adverse events occurred in the study. Overall in-hospital
ortality was 4.4% (14 patients); 3.2% (ﬁve patients) in the
ath-lab group and 5.5% (nine patients) in the prehospital
roup (p = 0.26). All but two deaths were cardiovascu-
ar. Major bleeding complications occurred in eight (2.5%)
atients, two (1.3%) in the cath-lab group and six (3.7%)
n the prehospital group (p = 0.28). In-stent thrombosis
ccurred in three (1.9%) patients in the cath-lab group and in
ne patient (0.6%) in the prehospital group (p = 0.36). One
a
t
T
taneous coronary intervention; TIMI: thrombolysis in myocardial
schaemic stroke occurred in the cath-lab group and two
aemorrhagic strokes in the prehospital group.
iscussion
he main result of this trial is that in patients with STEMI
reated in the prehospital setting with a high loading-dose
f clopidogrel and who were eligible to undergo primary
CI, prehospital administration of tiroﬁban was not asso-
iated with an increase in the initial patency rate of the
ulprit artery or a difference in complete ST-segment reso-
ution 1 h after the procedure compared with administration
f tiroﬁban in the cath lab.
In patients undergoing primary PCI, normal (TIMI 3) ﬂow
7] or coronary patency (TIMI 2—3 ﬂow) [8] before PCI
ave been associated with smaller myocardial infarctions
nd improved early and late survival. Most studies on early
dministration of GP IIb/IIIa inhibitors in patients undergo-
ng primary PCI have shown beneﬁts in terms of patency
ates [9] compared with later administration. However, all
hese studies were performed before the widespread use
f a high loading-dose of clopidogrel early in the manage-
ent of these patients. Compared with older studies [3], the
lunted difference in patency rate between the early and
ate groups in our study appears related to a higher patency
ate in the late group, reﬂecting the efﬁcacy on this end-
oint of an early high loading-dose of clopidogrel. Similar
esults were observed in the On-TIME2 and BRAVE-3 studies
5,10].
Resolution of ST-segment elevation after ﬁbrinolytic
herapy has been considered a marker of epicardial,fter the procedure, rates of complete ST-segment resolu-
ion on the electrocardiogram were similar in both groups.
hese results contrast with those of the On-TIME2 study
hat had shown improved ST-segment resolution in the early
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tiroﬁban group [5]. In On-TIME2, one-third of patients in
the control group received tiroﬁban and it was adminis-
tered after angiography. In AGIR2, all patients in the cath-lab
group had high-bolus tiroﬁban administered before vascular
access. Time from angiography to PCI was not registered in
our study, but we know from the ongoing registry in the RES-
CUe network, which is recruiting the same population, that
this delay is 15min (median, unpublished data). Therefore,
most patients in AGIR2 had GP IIb/IIIa inhibitors on board at
least 20min before PCI. This delay is enough to allow ade-
quate platelet inhibition by high bolus-dose tiroﬁban and
might explain the similar rates in complete ST-segment res-
olution [11—13].
The systematic use of GP IIb/IIIa inhibitors in STEMI had
been questioned by the negative results of the BRAVE-3
[10] and FINESSE [14] studies and the ambivalent results of
the On-TIME2 study [5]. However, a subpopulation (those
managed very early) could beneﬁt from the early initiation
strategy. In AGIR2, shorter delays from onset of chest pain to
tiroﬁban initiation and longer duration of treatment seem to
improve pre-PCI rates of ST-segment resolution and coronary
patency. Delays to diagnosis have also been found to inﬂu-
ence outcomes with eptiﬁbatide [15] and abciximab [10].
In patients pretreated with a 600mg loading dose of clopi-
dogrel, timing of the initiation of the GP IIb/IIIa inhibitor
in relation to symptom onset might be critical for prepro-
cedural endpoints, but its signiﬁcance on postprocedural
outcome is uncertain.
Our study has several limitations. It was open-label and
data on angiograms were investigator-reported. To com-
pensate for these limitations, we restricted our analysis to
the patency rate (TIMI 2—3 ﬂow), which is a more robust
endpoint regarding interobserver variability. The initial sam-
ple size calculation rested on data that were available in
2006 when the study was designed. Results of the BRAVE-
3 [10] and On-TIME2 [5] studies were not available at that
time. The higher than expected rate of patency in the late
tiroﬁban group, similar to the one observed in the OnTime-2
study, lowered the power of the study to detect a difference.
Conclusions and clinical implications
In patients with acute myocardial infarction managed in
the prehospital setting with a 600mg loading dose of clopi-
dogrel, immediate initiation of tiroﬁban did not improve
signiﬁcantly preprocedural or postprocedural patency and
ST-segment resolution. These results do not support the
need to initiate GP IIb/IIIa inhibitor therapy in all patients in
the prehospital setting. Further studies could help to clarify
the beneﬁt of GP IIb/IIIa initiation in patients managed very
early in the prehospital setting.
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